https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
01). The same trend was observed with CMS (mean-difference 17.7 and 19.8, respectively, p0.01). At week 12, 18 patients (60.0%) reported a subjective improvement. At week 12, in non-responders (n=14) US detected inflammatory changes and/or progression of tendon tear in 7 (50.0%) patients and no relevant changes in 7 (50.0%). US-guided STABHA injections followed by rehabilitation therapy were found effective in improving both pain and shoulder function at the 12-week follow-up. In half of the non-responders, US allo
Like
Comment
Share
